Industry joins drive against non-communicable diseases
Tackling non-communicable diseases (NCDs) is the focus of a framework launched by the International Federation of Pharmaceutical Manufacturers and Associations.
An estimated half of all deaths caused by NCDs are preventable and over 1,500 medicines for major NCDs are currently in the pipeline, the IFPMA says. Its ten-point “Framework for action for the prevention and control of non-communicable diseases” unites the global drug research industry in support of the World Health Organization’s five-year NCD action plan.
The framework lists specific areas of action to tackle NCDs, including innovation, prevention, access and affordability and health education, and emphasises the role of partnerships and dialogue.
The document lays the groundwork for a United Nations high-level meeting on NCDs, due to take place on 19–20 September 2011, which aims to secure a pledge from heads of state to address the rise of NCDs.
Director general of the IFPMA Eduardo Pisani said: “The framework is just the beginning; our vision is to work with others to identify what can be done in practice to help poor people to access the care and treatment they need.
“Together we want to find ideas for concrete actions to put on the table in the aftermath of the UN NCD summit in September. The framework is our roadmap for this work.”
Earlier this month delegates at the Commonwealth Pharmacists Association conference in South Africa set out a commitment to combating NCDs within the Commonwealth (PJ Online, 10 June 2011).
Citation: The Pharmaceutical Journal URI: 11079181
Recommended from Pharmaceutical Press